Replies to post #599834 on NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

Doc logic, I think your hypothesis will need to be tested in clinical trials.

I believe that NWBio will soon conduct basket trials for DCVax Direct for multiple solid tumor cancers, (colon, pancreas, ovarian, lung, etc.) and 1 arm will be standard of care (SOC) for each solid tumor cancer type, then 1 treatment arm will be DCVax Direct alone, then another arm will combine DCVax Direct and poly-ICLC (to hyper-activate and further mature the dendritic cells in vivo), then another arm that combines DCVax Direct and poly-ICLC + PD-1 inhibitor, then the last arm will combine DCVax Direct and poly-ICLC + PD-1 inhibitor + CSF-1R inhibitor.